Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer - Full Text View

Purpose

RATIONALE: Hyperbaric oxygen therapy may be effective in repairing damaged tissue and reducing lymphedema caused by radiation therapy for cancer.

PURPOSE: This randomized phase II trial is studying hyperbaric oxygen to see how well it works compared to standard therapy in treating chronic arm lymphedema in patients who have undergone radiation therapy for cancer.

Condition	Intervention	Phase
Breast Cancer Cancer-Related Problem/Condition	Drug: hyperbaric oxygen	Phase II

Genetics Home Reference related topics:

breast cancer lymphedema-distichiasis syndrome

MedlinePlus related topics:

Breast Cancer Cancer Lymphedema

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Supportive Care, Randomized, Active Control

Official Title:	Randomized Phase II Trial Of Hyperbaric Oxygen Therapy In Patients With Chronic Arm Lymphoedema After Radiotherapy For Cancer

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Volume of the affected limb, expressed as a percentage of the contralateral limb Volume on the day of measurement, as measured by perometer 12 months after baseline assessment

Secondary Outcome Measures:

Patient self-assessments, using specific quality of life scale in upper limb lymphoedema and the UK SF-36 Health Survey Questionnaire, at 3, 6, 9 and 12 months after baseline assessment
99Tc-nanocolloid clearance rate as measured by quantitative lymphoscintigraphy 12 months after baseline assessment
Extracellular water content as measured by EdemaMeter (bioimpedance measurements) 12 months after baseline assessment

Estimated Enrollment:	63
Study Start Date:	April 2004

Detailed Description:

OBJECTIVES:

Primary

Compare the efficacy of hyperbaric oxygen (HBO) therapy vs standard management, in terms of reduction of lymphedema, in patients with chronic arm lymphedema after radiotherapy for cancer.

Secondary

Determine the mechanisms of tissue reperfusion and healing in patients treated with HBO therapy.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients undergo hyperbaric oxygen therapy over 90 minutes 5 days a week for 6 weeks.
Arm II: Patients receive standard management. Patients are followed at 3, 6, 9, 12, and 15 months.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 63 patients (42 for arm I and 21 for arm II) will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

History of early breast cancer (T1-3, N0-1, M0)
Prior breast surgery with or without axillary dissection
Prior breast/chest wall radiotherapy with or without radiotherapy to the supraclavicular fossa and/or axilla, completed at least 2 years ago
Arm lymphedema
- At least 15% increase in arm volume
No evidence of cancer recurrence
Hormone receptor status:
- Not specified

PATIENT CHARACTERISTICS:

Age

Over 18

Sex

Female or male

Menopausal status

Not specified

Performance status

Not specified

Life expectancy

Not specified

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Not specified

Pulmonary

No chronic obstructive airway disease
No bullous lung disease
No acute or chronic pulmonary infection
No uncontrolled asthma
No untreated pneumothorax

Other

Physically and psychologically fit for HBO therapy
No claustrophobia
No epilepsy
No eustachian tube dysfunction
No recurrent attacks of vertigo
No contraindication to MRI (e.g., intracranial ferrous material)

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

Not specified

Radiotherapy

See Disease Characteristics

Surgery

See Disease Characteristics
No prior ear operations

Other

No prior hyperbaric oxygen (HBO) therapy, except as treatment for decompression illness

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00077090

Locations


United Kingdom, England
	Diving Diseases Research Centre
	Plymouth, England, United Kingdom, PL6 8BU
	Hull Royal Infirmary
	Hull, England, United Kingdom, HU3 2KZ
	London Hyperbaric Medicine Limited at Whipps Cross Hospital
	London, England, United Kingdom, E11 1NR
	Royal Hospital Haslar
	Gosport, England, United Kingdom, PO12 2AA
	Royal Marsden NHS Foundation Trust - Surrey
	Sutton, England, United Kingdom, SM2 5PT

Sponsors and Collaborators

Institute of Cancer Research, United Kingdom

Investigators


Study Chair:	John R. Yarnold, MD, FRCR	Royal Marsden - Surrey

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000349496, RMNHS-HOT, EU-20337
First Received:	February 10, 2004
Last Updated:	October 18, 2008
ClinicalTrials.gov Identifier:	NCT00077090
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

lymphedema

radiation fibrosis

perioperative/postoperative complications

stage I breast cancer

stage II breast cancer

stage IIIA breast cancer

Study placed in the following topic categories:

Lymphedema

Lymphatic Diseases

Skin Diseases

Postoperative Complications

Fibrosis

Breast Neoplasms

Radiation Pneumonitis

Breast Diseases

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	Institute of Cancer Research, United Kingdom
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00077090